Research Type: Reports
We conduct thorough investigations and studies of related various aspects of drug prices. When concluded, they are published to share our findings with academic, policymakers, and the public.
-
Xeljanz, the FDA, and nine years of patient harm
-
Atypical antipsychotics: Decades of use, unfathomable harms
-
Medicare Part B Premium Dynamics Explained
-
Comparing Factors that Influence Pharmaceutical Pricing and Access in the US and five other Countries
-
Biosimilars in Medicare Part D: pricing dynamics and considerations
-
Evaluating Industry’s Drug Pricing Claims
-
Production Plus Profit Pricing (P-quad) FAQ
-
Biosimilars: Market Changes do not equal policy success
-
Ethics of Clinical Trials to Evaluate Biosimilars
-
Bottom-Up Pricing Estimate for P-quad